Assembly Biosciences (ASMB) Revenue (2017 - 2026)

Assembly Biosciences' Revenue history runs 9 years deep, the most recent figure standing at $8.2 million for Q1 2026.

• On a quarterly basis, Revenue fell 12.8% year-over-year to $8.2 million in Q1 2026; TTM through Mar 2026 was $71.1 million, a 121.11% increase from a year earlier, with the FY2025 full-year figure at $72.3 million, up 153.52% from the prior year.
• Revenue retreated to $8.2 million in Q1 2026 per ASMB's latest filing, from $42.5 million in the prior quarter.
• Across five years, Revenue topped out at $42.5 million in Q4 2025 and bottomed at $5.8 million in Q1 2024.
• The 4-year median for Revenue is $8.4 million (2024), against an average of $11.6 million.
• Across the five-year window, Revenue jumped 477.26% in 2025 and retreated 12.8% in 2026, its largest moves.
• Year by year, Revenue stood at $7.2 million in 2023, then advanced by 2.71% to $7.4 million in 2024, then soared by 477.26% to $42.5 million in 2025, then sank by 80.66% to $8.2 million in 2026.
• Per Business Quant, the three latest ASMB Revenue figures stand at $8.2 million (Q1 2026), $42.5 million (Q4 2025), and $10.8 million (Q3 2025).